Published by Frank Prenesti on 27th January 2020
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
URL: http://www.digitallook.com/dl/news/story/30158873/...